REG - BioVentix PLC - Appointment of Non-Executive Director

BioventixAnnouncement

24/02/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260224:nRSX0701Ua&default-theme=true

RNS Number : 0701U  BioVentix PLC  24 February 2026

Bioventix plc

("Bioventix" or the "Company")

Appointment of Non-Executive Director

 

Bioventix PLC (AIM: BVXP), a UK company specialising in the development and
commercial supply of high-affinity monoclonal antibodies for applications in
clinical diagnostics, is delighted to announce the appointment of Chris Yates
as independent Non-Executive Director, with effect from 1(st) March 2026.

Chris brings extensive board‑level and sector expertise, underpinned by over
20 years' experience operating within publicly listed company environments.
Over the past decade, Chris has led the development and growth of Abingdon
Health plc. Chris co-founded the business in 2008, initially serving as
Non-Executive Director and then in 2015 becoming Chief Executive Officer until
2025 when he was appointed President of Abingdon Health USA and Group Chief
Commercial Officer.  Chris also serves as a Non-Executive Director and
Chairman of the Audit Committee of AIM-listed Genedrive plc. Earlier in his
career, Chris was CFO of AIM-listed companies Immunodiagnostic Systems
Holdings PLC and Cozart plc.

Chris is a Chartered Accountant and has a degree in economics from the
University of Cambridge.

 

For further information please contact:

 Bioventix plc                                      Tel: 01252 728 001
 Peter Harrison            Chief Executive Officer

 Cavendish Capital Markets Limited                  Tel: 020 7220 0500
 Geoff Nash/Elysia Bough   Corporate Finance
 Nigel Birks/Harriet Ward  ECM

 

 

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce
a suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on AIM under the symbol BVXP.

 

Further disclosures pursuant to Rule 17 and Schedule Two, paragraph (g) of the
AIM Rules for Companies:

 

Chris Henry Francis Yates

The following information regarding the appointment of Chris Yates, aged 51,
is disclosed under Schedule 2(g) of the AIM Rules for Companies:

 Current directorships and/or partnerships     Past directorships and/or partnerships (within the last five years)
 Abingdon Analytical Limited                   Abingdon Health plc
 Compliance Solutions (Life Sciences) Limited  Serascience Limited
 IVDeology Holdings Limited
 IVDeology Limited
 IVDeology UKRP Limited
 Molecular Vision Limited
 Genedrive plc
 Foresite Diagnostics Limited
 Find Out from Home Inc.
 Abingdon Health USA Inc.

 

Chris Yates does not hold any shares in Bioventix.

There are no further disclosures to be made under Rule 17 and Schedule 2(g) of
the AIM Rules for Companies.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOATJMRTMTBTBMF



            Copyright 2019 Regulatory News Service, all rights reserved